Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.95 USD

45.95
9,987,365

+0.59 (1.30%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $45.64 -0.31 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing

by Zacks Equity Research

Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.

    Zacks Equity Research

    AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?

    by Zacks Equity Research

    AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.

      Zacks Equity Research

      Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y

      by Zacks Equity Research

      Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.

        Zacks Equity Research

        Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View

        by Zacks Equity Research

        Horizon Pharma (HZNP) Q4 results are driven by growth from the orphan unit and the rheumatology business.

          Zacks Equity Research

          Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?

          by Zacks Equity Research

          With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.

            Zacks Equity Research

            5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018

            by Zacks Equity Research

            Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.

              Zacks Equity Research

              Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)

              by Zacks Equity Research

              Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.

                Zacks Equity Research

                Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat

                by Zacks Equity Research

                Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.

                  Zacks Equity Research

                  Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss

                  by Zacks Equity Research

                  Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Bristol-Myers, Honda, Danaher, MetLife and V.F.

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Bristol-Myers, Honda, Danaher, MetLife and V.F.

                      Zacks Equity Research

                      Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

                      by Zacks Equity Research

                      Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

                        Zacks Equity Research

                        Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?

                        by Zacks Equity Research

                        Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.

                          Zacks Equity Research

                          AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

                          by Zacks Equity Research

                          Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.

                            Zacks Equity Research

                            Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)

                            by Zacks Equity Research

                            Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.

                              Zacks Equity Research

                              Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher

                              by Zacks Equity Research

                              Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

                                Zacks Equity Research

                                Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales

                                by Zacks Equity Research

                                Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.

                                  Zacks Equity Research

                                  Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock

                                  by Zacks Equity Research

                                  Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.

                                    Zacks Equity Research

                                    Exelixis Reports Positive Data From Thyroid Carcinoma Trial

                                    by Zacks Equity Research

                                    Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.

                                      Sweta Killa headshot

                                      Solid Q4 Earnings Drive Pharma ETF Outlook

                                      by Sweta Killa

                                      Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.

                                        Zacks Equity Research

                                        Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates

                                        by Zacks Equity Research

                                        Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.

                                          Zacks Equity Research

                                          Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

                                          by Zacks Equity Research

                                          Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

                                            Zacks Equity Research

                                            Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study

                                            by Zacks Equity Research

                                            Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.

                                              Zacks Equity Research

                                              Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

                                              by Zacks Equity Research

                                              Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

                                                Zacks Equity Research

                                                Excellent Earnings Despite Markets Downtrading

                                                by Zacks Equity Research

                                                Excellent Earnings Despite Markets Downtrading

                                                  Mark Vickery headshot

                                                  Markets Purge, Q4 Earnings Surge

                                                  by Mark Vickery

                                                  Although the market sell-off looks to continue into regular trading Monday, Q4 earnings results remain the strongest we've seen in a long time.